Company news
Nicox Sa (EURONEXT:ALCOX) news
Every Nicox Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nicox Announces NCX 470 NDA in China Accepted for Review
September 11, 2026
Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470
September 10, 2026
Nicox Announces Extension of Cash Runway
September 2, 2026
Nicox annonce l’extension de son horizon de trésorerie
September 1, 2026
Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
August 26, 2026
Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
August 9, 2026
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
July 1, 2026
Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
June 23, 2026
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
June 8, 2026
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
June 3, 2026
Nicox Provides Full Year 2025 Financial Results and Corporate Update
April 30, 2026
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
April 20, 2026
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
February 24, 2026
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
February 16, 2026
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
February 10, 2026
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
January 20, 2026
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionat...
January 12, 2026
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
January 5, 2026
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
December 16, 2025
Nicox Provides First Half 2025 Financial Results
October 23, 2025
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
October 2, 2025
GHO Capital Sells VISUfarma to Lupin
September 29, 2025
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
September 4, 2025
Nicox Announces Shareholder Q&A Webpage Available
August 26, 2025
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
August 21, 2025
Nicox Extends Existing Flexible Equity Financing
August 8, 2025
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
August 5, 2025
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicense...
July 17, 2025
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
June 30, 2025